These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 35175630)

  • 1. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
    Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
    Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria.
    Bernstein JA; Maurer M; Saini SS
    J Allergy Clin Immunol; 2024 May; 153(5):1229-1240. PubMed ID: 38141832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
    Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
    Owens TD; Brameld KA; Verner EJ; Ton T; Li X; Zhu J; Masjedizadeh MR; Bradshaw JM; Hill RJ; Tam D; Bisconte A; Kim EO; Francesco M; Xing Y; Shu J; Karr D; LaStant J; Finkle D; Loewenstein N; Haberstock-Debic H; Taylor MJ; Nunn P; Langrish CL; Goldstein DM
    J Med Chem; 2022 Apr; 65(7):5300-5316. PubMed ID: 35302767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.
    Langrish CL; Bradshaw JM; Francesco MR; Owens TD; Xing Y; Shu J; LaStant J; Bisconte A; Outerbridge C; White SD; Hill RJ; Brameld KA; Goldstein DM; Nunn PA
    J Immunol; 2021 Apr; 206(7):1454-1468. PubMed ID: 33674445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Bruton's tyrosine kinase in the immune system and disease.
    McDonald C; Xanthopoulos C; Kostareli E
    Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Fast and Clean BTK Inhibitor.
    Gabizon R; London N
    J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D; Wang J; Hong J
    Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
    Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
    Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
    J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTK Inhibitors in Haematology: Beyond B Cell Malignancies.
    Leitinger DE; Kaplan DZ
    Transfus Med Rev; 2022 Oct; 36(4):239-245. PubMed ID: 36376164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.